pc 15 0 19 1 d7 pc avanti Search Results


pc 15 0 19 1 d7 pc avanti  (Croda International Plc)
94
Croda International Plc pc 15 0 19 1 d7 pc avanti
Pc 15 0 19 1 D7 Pc Avanti, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pc+15+0+19+1+d7+pc+avanti/16%3A0-18%3A1+PE/pmc12886497-103-2-4
Average 94 stars, based on 1 article reviews
pc 15 0 19 1 d7 pc avanti - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
cholesterol d7  (Croda International Plc)
95
Croda International Plc cholesterol d7
Comparison of UHPSFC/MS results in discovery and qualification phases. ( A ) PCA of all samples (validation and training sets) in the discovery phase. ( B ) PCA of all samples (validation and training sets) in the qualification phase (red—cancer (T), blue—control (N), and green—QC). Selected samples were annotated for comparison purposes. Boxplots comparing the concentrations of samples obtained from patients with different pathological states (blue: control, orange: kidney cancer, light blue: prostate cancer, and pink: breast cancer) for the discovery phase (1) and qualification phase (2) for ( C ) <t>LPC</t> 18:2, ( D ) PC 36:2, ( E <t>)</t> <t>Cer</t> 42:1 using UHPSFC/MS.
Cholesterol D7, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pc+15+0+19+1+d7+pc+avanti/cholesterol-d7/pmc08514434-196-30-63
Average 95 stars, based on 1 article reviews
cholesterol d7 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier
sm d18  (Avanti Polar)
94
Avanti Polar sm d18
Comparison of UHPSFC/MS results in discovery and qualification phases. ( A ) PCA of all samples (validation and training sets) in the discovery phase. ( B ) PCA of all samples (validation and training sets) in the qualification phase (red—cancer (T), blue—control (N), and green—QC). Selected samples were annotated for comparison purposes. Boxplots comparing the concentrations of samples obtained from patients with different pathological states (blue: control, orange: kidney cancer, light blue: prostate cancer, and pink: breast cancer) for the discovery phase (1) and qualification phase (2) for ( C ) <t>LPC</t> 18:2, ( D ) PC 36:2, ( E <t>)</t> <t>Cer</t> 42:1 using UHPSFC/MS.
Sm D18, supplied by Avanti Polar, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pc+15+0+19+1+d7+pc+avanti/12%3A0+PS/ppr0373258-163-44-62
Average 94 stars, based on 1 article reviews
sm d18 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
pc 14 0 14 0  (Avanti Polar)
98
Avanti Polar pc 14 0 14 0
Comparison of UHPSFC/MS results in discovery and qualification phases. ( A ) PCA of all samples (validation and training sets) in the discovery phase. ( B ) PCA of all samples (validation and training sets) in the qualification phase (red—cancer (T), blue—control (N), and green—QC). Selected samples were annotated for comparison purposes. Boxplots comparing the concentrations of samples obtained from patients with different pathological states (blue: control, orange: kidney cancer, light blue: prostate cancer, and pink: breast cancer) for the discovery phase (1) and qualification phase (2) for ( C ) <t>LPC</t> 18:2, ( D ) PC 36:2, ( E <t>)</t> <t>Cer</t> 42:1 using UHPSFC/MS.
Pc 14 0 14 0, supplied by Avanti Polar, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pc+15+0+19+1+d7+pc+avanti/14%3A0+PC/pmc08514434-196-36-63
Average 98 stars, based on 1 article reviews
pc 14 0 14 0 - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier
antibody titer  (ATCC)
93
ATCC antibody titer
Comparison of UHPSFC/MS results in discovery and qualification phases. ( A ) PCA of all samples (validation and training sets) in the discovery phase. ( B ) PCA of all samples (validation and training sets) in the qualification phase (red—cancer (T), blue—control (N), and green—QC). Selected samples were annotated for comparison purposes. Boxplots comparing the concentrations of samples obtained from patients with different pathological states (blue: control, orange: kidney cancer, light blue: prostate cancer, and pink: breast cancer) for the discovery phase (1) and qualification phase (2) for ( C ) <t>LPC</t> 18:2, ( D ) PC 36:2, ( E <t>)</t> <t>Cer</t> 42:1 using UHPSFC/MS.
Antibody Titer, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pc+15+0+19+1+d7+pc+avanti/Lyssavirus%2C+rabies+virus%2C+Strain+CVS-11/us10550174-4958-157-161
Average 93 stars, based on 1 article reviews
antibody titer - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
iu 2 5 iu  (ATCC)
90
ATCC iu 2 5 iu
Comparison of UHPSFC/MS results in discovery and qualification phases. ( A ) PCA of all samples (validation and training sets) in the discovery phase. ( B ) PCA of all samples (validation and training sets) in the qualification phase (red—cancer (T), blue—control (N), and green—QC). Selected samples were annotated for comparison purposes. Boxplots comparing the concentrations of samples obtained from patients with different pathological states (blue: control, orange: kidney cancer, light blue: prostate cancer, and pink: breast cancer) for the discovery phase (1) and qualification phase (2) for ( C ) <t>LPC</t> 18:2, ( D ) PC 36:2, ( E <t>)</t> <t>Cer</t> 42:1 using UHPSFC/MS.
Iu 2 5 Iu, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pc+15+0+19+1+d7+pc+avanti/Auricularia+fuscosuccinea+(Montagne)+Farlow%2C+teleomorph/us10550174-4958-47-161
Average 90 stars, based on 1 article reviews
iu 2 5 iu - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
lymph node biopsy  (ATCC)
90
ATCC lymph node biopsy
Comparison of UHPSFC/MS results in discovery and qualification phases. ( A ) PCA of all samples (validation and training sets) in the discovery phase. ( B ) PCA of all samples (validation and training sets) in the qualification phase (red—cancer (T), blue—control (N), and green—QC). Selected samples were annotated for comparison purposes. Boxplots comparing the concentrations of samples obtained from patients with different pathological states (blue: control, orange: kidney cancer, light blue: prostate cancer, and pink: breast cancer) for the discovery phase (1) and qualification phase (2) for ( C ) <t>LPC</t> 18:2, ( D ) PC 36:2, ( E <t>)</t> <t>Cer</t> 42:1 using UHPSFC/MS.
Lymph Node Biopsy, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pc+15+0+19+1+d7+pc+avanti/Epichloe+bromicola+Leuchtmann+et+Schardl/us10550174-4958-89-161
Average 90 stars, based on 1 article reviews
lymph node biopsy - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Comparison of UHPSFC/MS results in discovery and qualification phases. ( A ) PCA of all samples (validation and training sets) in the discovery phase. ( B ) PCA of all samples (validation and training sets) in the qualification phase (red—cancer (T), blue—control (N), and green—QC). Selected samples were annotated for comparison purposes. Boxplots comparing the concentrations of samples obtained from patients with different pathological states (blue: control, orange: kidney cancer, light blue: prostate cancer, and pink: breast cancer) for the discovery phase (1) and qualification phase (2) for ( C ) LPC 18:2, ( D ) PC 36:2, ( E ) Cer 42:1 using UHPSFC/MS.

Journal: Scientific Reports

Article Title: Plasma lipidomic profiles of kidney, breast and prostate cancer patients differ from healthy controls

doi: 10.1038/s41598-021-99586-1

Figure Lengend Snippet: Comparison of UHPSFC/MS results in discovery and qualification phases. ( A ) PCA of all samples (validation and training sets) in the discovery phase. ( B ) PCA of all samples (validation and training sets) in the qualification phase (red—cancer (T), blue—control (N), and green—QC). Selected samples were annotated for comparison purposes. Boxplots comparing the concentrations of samples obtained from patients with different pathological states (blue: control, orange: kidney cancer, light blue: prostate cancer, and pink: breast cancer) for the discovery phase (1) and qualification phase (2) for ( C ) LPC 18:2, ( D ) PC 36:2, ( E ) Cer 42:1 using UHPSFC/MS.

Article Snippet: Non-endogenous lipids were used as internal standards (IS) for quantitative analysis, i.e. , MG 19:1/0:0/0:0, DG 12:1/0:0/12:1, and TG 19:1/19:1/19:1 from Nu-ChekPrep (Elysian, MN, USA); CE 16:0 D7, Cer d18:1/12:0, cholesterol D7, LPC 17:0/0:0, LPE 14:0/0:0, PC 14:0/14:0, PC 22:1/22:1, PE 14:0/14:0, PI 15:0/18:1 D7, SM d18:1/12:0, PS 14:0/14:0, PA 14:0/14:0, PG 14:0/14:0, LPG 14:0/0:0, HexCer d18:1/12:0, Hex2Cer d18:1/12:0, and SHexCer d18:1/12:0 from Avanti Polar Lipids (Alabaster, AL, USA).

Techniques: